title: Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients.
abstract: BACKGROUND
  Several reports have shown a prolonged survival after surgical treatment of pulmonary metastases from soft tissue sarcomas. However, it is still unclear which prognostic factors predict a favorable outcome. Series are not comparable and the data are conflicting. Therefore, a multi-institutional study was undertaken to analyze prognostic factors in selecting patients for resection of pulmonary metastases from soft tissue sarcomas.
  
  
  METHODS
  This report is a retrospective study of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group. Two hundred fifty-five patients underwent complete resection of lung metastases from soft tissue sarcomas. Cases with chondrosarcoma and small round cell sarcomas like Ewing sarcoma were excluded.
  
  
  RESULTS
  The 3 year and 5 year overall postmetastasectomy survival rates were 54% and 38%, respectively. The disease free postmetastasectomy survival rates were 42% and 35%, respectively. Analysis of prognostic factors for a more favorable outcome revealed disease free intervals of 2.5 years or more, following a resection with microscopically free margins, age less than 40 years, and Grade I and II tumors. These prognostic factors have an independent influence on overall survival, using a multivariate Cox regression model.
  
  
  CONCLUSIONS
  Surgical excision of lung metastases from soft tissue sarcomas is well accepted and should be considered as a first line of treatment if preoperative evaluation indicates that complete clearance of the metastases is possible. Further investigation is needed before chemotherapy can be recommended as additional therapy.
authors.affiliation: Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: A N
authors.initials: AN
authors.lastname: van Geel
authors.forename: U
authors.initials: U
authors.lastname: Pastorino
authors.forename: K W
authors.initials: KW
authors.lastname: Jauch
authors.forename: I R
authors.initials: IR
authors.lastname: Judson
authors.forename: F
authors.initials: F
authors.lastname: van Coevorden
authors.forename: J M
authors.initials: JM
authors.lastname: Buesa
authors.forename: O S
authors.initials: OS
authors.lastname: Nielsen
authors.forename: A
authors.initials: A
authors.lastname: Boudinet
authors.forename: T
authors.initials: T
authors.lastname: Tursz
authors.forename: P I
authors.initials: PI
authors.lastname: Schmitz
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome